Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 Weeks Assessed Using a Matching-Adjusted Indirect Comparison

Abstract Introduction Matching-adjusted indirect comparisons (MAIC) were used to assess the relative efficacy of bimekizumab 160 mg every 4 weeks (Q4W) compared to guselkumab 100 mg Q4W or every 8 weeks (Q8W) at 48/52 weeks in patients with psoriatic arthritis (PsA) who were biologic disease-modifyi...

Full description

Bibliographic Details

Published in:	Rheumatology and Therapy
Main Authors:	Richard B. Warren, Iain B. McInnes, Peter Nash, Jean-Marie Grouin, Nikos Lyris, Damon Willems, Vanessa Taieb, Jason Eells, Philip J. Mease
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2024-03-01
Subjects:	ACR Bimekizumab Biologics Guselkumab IL-17 IL-23
Online Access:	https://doi.org/10.1007/s40744-024-00659-0